IM
IMVT.US Immunovant Inc
- Market cap
- USD 7.07B
- P/E
- -
- P/B
- 10.77x
- ROE
- -76.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is IMVT.US undervalued?
Graham numberThe Graham number of Immunovant Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immunovant Inc fundamental analysis
No fundamental analysis for Immunovant Inc yet.
Immunovant Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, Nort…
Full company profileImmunovant Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Immunovant Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.2M |
| Gross Profit | - | - | -21.0K | -998K | -1.23M | -1.32M | -231K | -377K | -409K | - |
| Operating Income | -450.00 | -450.00 | -59.7M | -108M | -156M | -208M | -270M | -438M | -533M | -515M |
| EBITDA | - | -28.4K | -65.6M | -108M | -157M | -198M | -259M | -413M | -505M | -501M |
| Net Income | -450.00 | -450.00 | -66.4M | -107M | -157M | -211M | -259M | -414M | -506M | -501M |
| EPS | 0.00 | 0.00 | -1.54 | -1.22 | -1.43 | -1.71 | -1.88 | -2.73 | -2.77 | -2.42 |
| Balance Sheet | ||||||||||
| Total Assets | 113K | 405K | 109M | 412M | 516M | 406M | 667M | 776M | 957M | 761M |
| Total Liabilities | 1.61M | 380K | 15.3M | 21.0M | 45.7M | 43.3M | 49.0M | 68.8M | 104M | 104M |
| Shareholders' Equity | -1.50M | 24.6K | 94.1M | 391M | 470M | 362M | 618M | 707M | 853M | 657M |
| Cash & Short-term Investments | - | 325K | 101M | 400M | 494M | 377M | 635M | 714M | 902M | 722M |
| Total Debt | - | 300K | 3.19M | 3.42M | 2.36M | 1.22M | 138K | 98.0K | 72.0K | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | - | -28.5M | -53.4M | -83.3M | -106M | -188M | -214M | -376M | -407M | -415M |
| Capital Expenditure | 0.00 | 52.0K | 31.0K | 210K | 254K | 197K | 360K | 759K | 8.00K | 0.00 |
| Free Cash Flow | - | -28.6M | -53.4M | -83.5M | -106M | -188M | -215M | -377M | -407M | -415M |
| Ratios | ||||||||||
| ROE | - | -1.8% | -70.6% | -27.4% | -33.4% | -58.2% | -42.0% | -58.5% | -59.3% | -76.3% |
| ROA | -0.4% | -0.1% | -60.7% | -26.0% | -30.4% | -52.0% | -38.9% | -53.3% | -52.8% | -65.8% |
| Net Profit Margin | - | - | - | - | - | - | - | - | - | -3,530.2% |
| Debt to Equity | - | 12.22x | 0.03x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Immunovant Inc dividends
Immunovant Inc has not paid dividends in the last 9 fiscal years.
Who owns Immunovant Inc
- Insiders 56.20%
- Institutions 43.80%
- Public & others 0.00%
- Shares outstanding 207M
- Free float 92.2M
Top funds holding IMVT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 5.09M | 2.50% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.02M | 1.48% | +15.66% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.26M | 1.11% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 2.19M | 1.08% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 2.09M | 1.03% | +10.86% | Sep 2026 |
| Fidelity Growth Company K6 | 1.41M | 0.69% | 0.00% | Aug 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.17M | 0.57% | +7.20% | Sep 2026 |
| Fidelity Series Growth Company | 1.09M | 0.54% | -0.23% | Aug 2026 |
| Fidelity Small Cap Index | 934K | 0.46% | +0.14% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 810K | 0.40% | -0.38% | Oct 2026 |
| PGIM Jennison Small Company A | 742K | 0.37% | 0.00% | Sep 2026 |
| Candriam Eqs L Biotech C USD Cap | 661K | 0.33% | -2.88% | Apr 2026 |
| iShares Biotechnology ETF | 658K | 0.32% | -0.19% | Oct 2026 |
| T. Rowe Price Small-Cap Stock | 655K | 0.32% | -0.57% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 642K | 0.32% | 0.00% | Sep 2026 |
| abrdn Healthcare Investors | 537K | 0.26% | +39.21% | Oct 2026 |
| Vanguard Russell 2000 ETF | 503K | 0.25% | +2.49% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 429K | 0.21% | +0.24% | Oct 2026 |
| Fidelity Contrafund | 374K | 0.18% | -26.37% | Sep 2026 |
| Fidelity Extended Market Index | 364K | 0.18% | -2.97% | Sep 2026 |
Top institutions holding IMVT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 16.2M | 7.96% | -4.49% | Jun 2026 |
| Deep Track Capital, LP | 9.34M | 4.59% | -18.96% | Jun 2026 |
| BlackRock Inc | 7.18M | 3.53% | +9.22% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 5.81M | 2.86% | +275.49% | Jun 2026 |
| Baker Bros Advisors LP | 5.44M | 2.67% | -0.42% | Jun 2026 |
| State Street Corp | 4.62M | 2.27% | +1.74% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.53M | 2.23% | +16.97% | Jun 2026 |
| TCG Crossover Management, LLC | 4.46M | 2.19% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.91M | 1.92% | +5.55% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.64M | 1.79% | +0.51% | Jun 2026 |
| Jennison Associates LLC | 3.31M | 1.63% | +3.55% | Jun 2026 |
| RTW INVESTMENTS, LLC | 3.18M | 1.56% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 2.33M | 1.15% | -13.00% | Jun 2026 |
| Geode Capital Management, LLC | 2.23M | 1.10% | +6.81% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 2.22M | 1.09% | -38.49% | Jun 2026 |
| Woodline Partners LP | 1.98M | 0.97% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.83M | 0.90% | +438.63% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.75M | 0.86% | -1.90% | Jun 2026 |
| Armistice Capital, LLC | 1.74M | 0.85% | -51.30% | Jun 2026 |
| Alpine Partners VI, LLC | 1.38M | 0.68% | -47.86% | Jun 2026 |
Immunovant Inc company profile
- Company name
- Immunovant Inc
- Ticker
- IMVT.US
- Exchange
- USA Stocks
- Listed since
- Jun 21, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 315
- Fiscal year end
- March
- Address
- 1000 Park Forty Plaza, Durham, NC, United States, 27713
- Phone
- 917 410 3120
- Website
- immunovant.com
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant Inc management
8- Dr. Frank M. Torti M.B.A., M.D.Executive Chairperson of the Board · born 1979
- Dr. Eric Venker M.D., Pharm.D.CEO & Director · born 1987
- Ms. Melanie Gloria B.S.N.Chief Operating Officer · born 1978
- Dr. Jay S. Stout M.S., Ph.D.Chief Technology Officer · born 1963
- Mr. Christopher A. Van Tuyl Esq., J.D.Chief Legal Officer & Corporate Secretary · born 1975
- Ms. Christine BlodgettSenior Vice President of Human Resources
- Ms. Becky MerlinaSenior VP & Global Head of Quality
- Ms. Yan Zheng M.S., Ph.D.Senior Vice President of Biostatistics, Programming & Data Management